Infographic- Project Optimus
What Oncology Drug Developers Should Expect from the FDA’s Project Optimus. With deep experience in…
Certara2022年6月15日
Reflections on the Recent ICH E11A Pediatric Extrapolation Guideline
The ICH E11A draft Guideline on Paediatric Extrapolation was released on 4 April 2022 entering a public…
Certara2022年6月14日
eCTD Submission Challenges
Industry standards are continually evolving, creating an environment of rapid change. With change comes challenges.…
Certara2022年6月1日
PK Modeling Supports Dosing Strategy for Patients with Hepatic Impairment
Primary biliary cholangitis (PBC) is a chronic disease that impedes bile flow from the liver,…
Certara2022年5月31日
Learn how to shorten the drug discovery design-make-test-analyze cycle with D360
Researchers use D360 to query research data efficiently across different data sources and to create…
Certara2022年5月25日
The Utility of Model-Informed Drug Development for Rare Diseases
Model-informed drug development (MIDD) is a network of closely integrated ecosystems that can seamlessly position…
Certara2022年5月20日
Certara Earns 2022 Great Place to Work Certification™
Princeton, NJ, 2022年5月17日. Certara, Inc., a global leader in biosimulation, today announced that…
Certara2022年5月17日
Ask Me Anything: Career Opportunities in Regulatory & Medical Writing
Have you ever wondered what it would be like to be a Regulatory or Medical…
Certara2022年5月12日
Approaches to Address the Regulatory Requirements for System Qualification of the Simcyp Simulator
Physiologically-based pharmacokinetic (PBPK) modeling is being increasingly used in drug development to avoid unnecessary clinical…
Certara2022年5月9日
